menu
    • menu
    [{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Ottawa Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Ottawa Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Ottawa Hospital"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Merck","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Merck"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INT230-6","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Portage Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"IMM60","moa":"iNKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Intensity Therapeutics \/ Intensity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Intensity Therapeutics \/ Intensity Therapeutics"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Intensity Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"2-hydroxybenzoyl Amino Octanoate","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injectable\/Injection","sponsorNew":"Intensity Therapeutics \/ The Benchmark Company","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ The Benchmark Company"},{"orgOrder":0,"company":"Intensity Therapeutics","sponsor":"SAKK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Vinblastine Sulfate","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Intensity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intensity Therapeutics \/ SAKK","highestDevelopmentStatusID":"8","companyTruncated":"Intensity Therapeutics \/ SAKK"}]

    Find Clinical Drug Pipeline Developments & Deals by Intensity Therapeutics

    Menu

    Intensity Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : SAKK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Intensity Therapeutics, Sakk Ink Agreement for Phase 2 Trial in Early-Stage Cancer

                            Details : The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 13, 2024

                            Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : SAKK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : The Benchmark Company

                            Deal Size : $19.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5...

                            Details : The company intends to use the net proceeds for the development of INT230-6, a formulation consisting of its proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplat...

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 30, 2023

                            Lead Product(s) : 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : The Benchmark Company

                            Deal Size : $19.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direc...

                            Details : INT230-6 is designed for direct intratumoral injection, composed of two proven, potent anti-cancer agent, cisplatin and vinblastine, and penetration enhancer molecule that help disperse potent cytotoxic drugs throughout tumors for diffusion into cancer c...

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 18, 2022

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMM60,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Portage Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 St...

                            Details : Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.

                            Brand Name : IMM60

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : IMM60,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Portage Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with ...

                            Details : Data show INT230-6 (Cisplatin), is designed for direct intratumoral injection is well tolerated and elicits both direct tumor killing and immune activating effects in a variety of solid tumors.

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 03, 2022

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT230-6

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinic...

                            Details : INT230-6, Intensity’s lead proprietary investigational product candidate, is designed for direct intratumoral injection was discovered using Intensity’s proprietary DfuseRx℠ technology platform.

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 03, 2021

                            Lead Product(s) : INT230-6

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Intensity Therapeutics’ INT230-6 Effective as Either Monotherapy or in Combination with Checkpoint Inhibitor...

                            Details : Data in the first poster show that INT230-6, monotherapy or in combination with pembrolizumab, is well tolerated and elicits both direct tumor killing and abscopal effects. The second presentation reports similar results of INT230-6 with or without ipili...

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 02, 2021

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Ottawa Hospital

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements

                            Details : The Ottawa Hospital and The Ontario Institute for Cancer Research (OICR) to conduct a Phase II Randomized, Window of Opportunity (WOO) trial evaluating clinical and biological effects of intratumoral INT230-6 vs. no treatment in early stage breast cancer...

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 24, 2021

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Salcaprozate Sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Ottawa Hospital

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study in Patients with Ad...

                            Details : Local delivery of INT230-6 as monotherapy into tumors induced an immune response with increases of activated CD4+ and CD8+ T-cells in the tumor without any immune-related adverse events.

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 11, 2020

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Intensity Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® ...

                            Details : The scPharmaceuticals management team will discuss the FUROSCIX® development plan. FUROSCIX® is an investigational, proprietary formulation of furosemide that is administered subcutaneously via a wearable on-body, drug delivery system, for outpatient s...

                            Brand Name : INT230-6

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 17, 2020

                            Lead Product(s) : Cisplatin,Vinblastine Sulfate,Ipilimumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth